TABLE 2.
CTL activities in patients infected with subtype B HIV-1
| Target antigen | LUa for donor:
|
|||||||
|---|---|---|---|---|---|---|---|---|
| CO3M | T051 | BI02 | MIO7 | MI10 | MI21 | W39 | W44 | |
| Subtype B HIV-1 | ||||||||
| Env/LAI | 143 | <3 | 87 | 18 | 83 | 134 | 28 | 486 |
| Gag/LAI | 77 | 28 | 178 | 84 | 108 | 507 | 57 | 567 |
| Pol/LAI | <3 | 77 | 75 | 159 | 77 | 312 | 37 | 128 |
| Nef/LAI | 93 | 34 | 127 | 72 | 23 | 219 | 61 | <3 |
| Subtype A HIV-1 | ||||||||
| Env/OUG | 125 | <3 | <3 | <3 | 18 | <3 | 62 | 42 |
| Gag/CAR | 38 | <3 | <3 | 43 | 47 | <3 | 59 | 56 |
| Pol/CAR | <3 | 42 | 45 | 83 | 23 | <3 | 17 | 103 |
| Nef/CAR | 73 | 18 | 96 | 28 | 12 | 49 | 23 | <3 |
| HIV-2 | ||||||||
| Env/ROD | <3 | <3 | <3 | <3 | <3 | <3 | <3 | <3 |
| Gag/ROD | <3 | <3 | <3 | <3 | <3 | <3 | NT | <3 |
| Nef/ROD | <3 | <3 | <3 | <3 | <3 | <3 | <3 | <3 |
a
LU were calculated as described in Materials and Methods. NT, not tested.